Pharsight

1. List of Saphris drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7741358	ALLERGAN	Crystal form of asenapine maleate	Apr, 2026 (3 years from now)
US8022228	ALLERGAN	Crystal form of asenapine maleate	Apr, 2026 (3 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7741358 (Pediatric)	ALLERGAN	Crystal form of asenapine maleate	Oct, 2026 (3 years from now)
US8022228 (Pediatric)	ALLERGAN	Crystal form of asenapine maleate	Oct, 2026 (3 years from now)

Market Authorisation Date: 13 August, 2009

Treatment: Use of the atypical antipsychotic asenapine for treatment of schizophrenia in adults; Treatment of bipolar disorder and schizophrenia; Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: as adjunctive treatment to lithium or valproate in adults; Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: acute monotherapy of manic or mixed episodes in pediatric patients age 10-17; Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: acute monotherapy of manic or mixed episodes (ages 10 to adult); Method of treating manic or mixed episodes associated with bipolar disorder in pediatric patients; Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: maintenance monotherapy in adults

Dosage: TABLET;SUBLINGUAL